- Home
- SEZL vs AUTL Comparison
SEZL vs AUTL Comparison
Compare SEZL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- AUTL
- Stock Information
- Founded
- SEZL 2016
- AUTL 2014
- Country
- SEZL United States
- AUTL United Kingdom
- Employees
- SEZL N/A
- AUTL N/A
- Industry
- SEZL Diversified Financial Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEZL Finance
- AUTL Health Care
- Exchange
- SEZL Nasdaq
- AUTL Nasdaq
- Market Cap
- SEZL 1.2B
- AUTL 1.1B
- IPO Year
- SEZL N/A
- AUTL 2018
- Fundamental
- Price
- SEZL $385.00
- AUTL $3.08
- Analyst Decision
- SEZL Strong Buy
- AUTL Strong Buy
- Analyst Count
- SEZL 2
- AUTL 2
- Target Price
- SEZL $231.50
- AUTL $11.50
- AVG Volume (30 Days)
- SEZL 134.2K
- AUTL 2.3M
- Earning Date
- SEZL 11-07-2024
- AUTL 11-12-2024
- Dividend Yield
- SEZL N/A
- AUTL N/A
- EPS Growth
- SEZL 1005.78
- AUTL N/A
- EPS
- SEZL 9.51
- AUTL N/A
- Revenue
- SEZL $221,806,305.00
- AUTL $10,091,000.00
- Revenue This Year
- SEZL $49.16
- AUTL $816.67
- Revenue Next Year
- SEZL $31.93
- AUTL $374.47
- P/E Ratio
- SEZL $40.50
- AUTL N/A
- Revenue Growth
- SEZL 49.13
- AUTL 82.71
- 52 Week Low
- SEZL $9.75
- AUTL $2.94
- 52 Week High
- SEZL $454.16
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- SEZL 70.53
- AUTL 35.72
- Support Level
- SEZL $345.21
- AUTL $3.24
- Resistance Level
- SEZL $414.93
- AUTL $4.12
- Average True Range (ATR)
- SEZL 40.98
- AUTL 0.37
- MACD
- SEZL 14.06
- AUTL -0.09
- Stochastic Oscillator
- SEZL 73.62
- AUTL 8.48
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.